INSERT INTO drugs VALUES
    (23,'Ampicillin','A. Menarini Farmaceutica Internazionale SRL',172,32),
    (47,'Anastrozole','AbbVie Ltd',3199,54),
    (69,'AndroGel','Accord Healthcare Limited',1804,56),
    (64,'Annovera','Accord-UK Ltd',3706,21),
    (61,'Apalutamide','Advanced Accelerator Applications',2325,48),
    (60,'Apixaban','ADVANZ Pharma',1474,94),
    (37,'Apokyn','Aerona Clinical Limited',4236,25),
    (31,'Apriso','AGB-Pharma AB',1864,59),
    (32,'Aptiom','AGEPHA Pharma s.r.o.',2812,20),
    (68,'Aricept','Aguettant Ltd',166,17),
    (80,'Arimidex','Aimmune Therapeutics UK Limited',1757,60),
    (97,'Aripiprazole','AJ Vaccines A/S',1670,86),
    (44,'Aristada','Akcea Therapeutics UK Ltd',1036,41),
    (39,'Aromasin','Alan Pharmaceuticals',638,53),
    (46,'Ascorbic acid','Albireo Pharma',2337,97),
    (22,'Aspirin','Alcon Eye Care UK Limited',2843,70),
    (53,'Atenolol','Alexion Pharma UK Ltd',2657,76),
    (70,'Ativan','Alimera Sciences Limited',1592,15),
    (65,'Atomoxetine','ALK-Abello Ltd',1365,91),
    (58,'Atorvastatin','Allen & Hanburys Ltd',154,33),
    (21,'Atropine','Allergy Therapeutics',4201,79),
    (95,'Aubagio','Alliance Pharmaceuticals',1350,88),
    (42,'Augmentin','Almirall Limited',2500,43),
    (48,'Austedo','Alnylam UK Ltd',2722,22),
    (50,'Avsola','Alturix Limited',3625,81),
    (34,'Azathioprine','Amarin Pharmaceuticals Ireland Limited',2201,69),
    (76,'Azelastine','Amarox Limited',2815,24),
    (59,'Azilect','Amgen Ltd',253,44),
    (87,'Azithromycin','Amicus Therapeutics UK Ltd',3708,85),
    (9,'Azulfidine','AMRING SARL',3047,52),
    (75,'Eulexin','Amryt Pharmaceuticals DAC',1514,100),
    (38,'Euthyrox','Angelini Pharma UK-I Limited (Formerly Arvelle Therapeutics UK)',2988,66),
    (40,'Evenity','Aristo Pharma Limited',3051,78),
    (57,'Evista','AS Kalceks',576,39),
    (30,'Excedrin','Aspen',1973,9),
    (4,'Excedrin Migraine','Aspire Pharma Ltd',4465,42),
    (99,'Exemestane','Astellas Pharma Ltd',3369,64),
    (91,'Eylea','AstraZeneca UK Limited',4566,68),
    (11,'Ezetimibe','Atnahs Pharma UK Ltd',324,40),
    (8,'Herceptin','Aurobindo Pharma - Milpharm Ltd.',2380,8),
    (78,'Hiprex','axunio Pharma GmbH',749,12),
    (100,'Histrelin','Alturix Limited',1361,87),
    (51,'Hizentra','Amarin Pharmaceuticals Ireland Limited',4846,34),
    (81,'Humalog','Amarox Limited',1458,50),
    (26,'Humira','Amgen Ltd',3684,11),
    (62,'Humulin 70/30','Amicus Therapeutics UK Ltd',3251,23),
    (90,'Humulin N','AMRING SARL',4045,13),
    (28,'Humulin R','Amryt Pharmaceuticals DAC',3203,35),
    (14,'Humulin RU 500','Angelini Pharma UK-I Limited (Formerly Arvelle Therapeutics UK)',2300,28),
    (41,'Hycodan','Aristo Pharma Limited',2051,77),
    (7,'Hydralazine','AS Kalceks',3181,98),
    (6,'Levetiracetam','Aspen',4927,27),
    (82,'Levocetirizine','Aspire Pharma Ltd',1058,65),
    (12,'Levodopa','Astellas Pharma Ltd',2105,10),
    (66,'Levofloxacin','AstraZeneca UK Limited',2279,84),
    (94,'Levothyroxine','Atnahs Pharma UK Ltd',2350,75),
    (52,'Lexapro','Aurobindo Pharma - Milpharm Ltd.',4902,3),
    (63,'Lexette','axunio Pharma GmbH',1744,82),
    (33,'Lialda','A. Menarini Farmaceutica Internazionale SRL',4964,89),
    (74,'Lidex','AbbVie Ltd',1779,16);
